REFEREED PUBLICATIONS – IOWA STATE
[1] Rassnick KM, Bailey DB, Kamstock DA, LeBlanc CJ, Berger EP, Flory AB, Kiselow MA, Intile JL, Malone EK, Regan RC, Musser ML, Yanda N, Johannes CM. Evaulation of factors associated with survival in dogs with lymphoma treated with prednisone The Canine Lymphoma Steroid Only prospective clinical study: 109 cases (2016-17). Accepted by J Am Vet Med Assoc, June 2020. In Press
[2] Musser ML, Viall AK, Phillips RL, Hostetter JM, Johannes CM. RNA expression of prostaglandin EP4 receptor in canine osteosarcoma. Accepted by Can J Vet Res, April 2020. In Press
[3] Musser ML, Viall AK, Phillips RL, Hostetter JM, Johannes CM. Gene expression of prostaglandin EP4 receptor in three canine carcinomas. BMC Vet Res, 16:213, 2020. DOI: 10.1186/s12917-020-02431-2 https://bmcvetres.biomedcentral.com/track/pdf/10.1186/s12917-020-02431-2
[4] Johannes CM, Heinrich ERE, Musser ML, Andreasen CB. Hypercalcemia of malignancy associated with exocrine pancreatic adenocarcinoma in a dog. Vet Rec Case Rep;8:e001190, 2020. DOI: 10.1136/vetreccr-2020-001190. https://vetrecordcasereports.bmj.com/content/vetreccr/8/4/e001190.full…
[5] *Fowler BL, Johannes CM, O’Connor A, Collins D, Lustgarten J, Yuan C, Weishaar K, Sullivan K, Hume KR, Mahoney J, Vale B, Schubert A, Ball V, Cooley-Lock K, Curran KM, Nafe L, Gedney A, Weatherford M, LeVine DN. Ecological level analysis of primary lung tumors in dogs and cats and environmental radon activity. J Vet Intern Med, 34:2660-2670, 2020. DOI: 10.1111/jvim.15936. [Epub 03NOV2020] https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.15936
[6] Musser ML, Berger EP, Tripp CD, Clifford CA, Bergman PJ, Johannes CM. Safety evaluation of canine osteosarcoma vaccine, live listeria vector. Vet Comp Oncol, 2020. DOI: 10.1111/vco.12642 [Epub 30JUL2020] https://onlinelibrary.wiley.com/doi/epdf/10.1111/vco.12642
[7] De Ridder TR, Campbell JE, Burke-Schwarz C, Clegg D, Elliot EL, Geller S, Kozak W, Pittenger ST, Pruitt JB, Riehl J, White J, Weist ML, Johannes CM, Morton J, Jones PD, Schmidt PF, Gordon V, Reddell P. Randomized controlled clinical study evaluating efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). J Vet Intern Med, 2020. DOI: 10.1111/jvim.15806 [Epub 16JUN2020] https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.15806
[8] Reddell P, De Ridder T, Campbell J, Jones P, Morton J, Johannes CM, Brown G, Schmidt P, Gordon V. Wound formation, wound size and progression of wound healing following intratumoral treatment of canine mast cell tumors with tigilanol tiglate. Accepted by J Vet Intern Med, November 2020. In Press
[9] Jones PD, Campbell JE, Brown G, Johannes CM, Reddell P. Recurrence free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.Vet Intern Med, 2020. DOI: 10.1111/jvim.16018 [Epub 22DEC2020] https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.16018
[10] Fenger JM, Eward WC, Hendricks WPD, McNeil EA, Johannes C, Richard SB, Treml LS, Bruyette D, Mutsaers AJ, Woods JP, Clifford CA, Simons T, Zipfel S, Kang W, Thamm MD, Dybdal N, Lappin M, Khanna C. Delivering innovation to oncology drug development through cancer drug DISCO (Development Incentive Strategy using Comparative Oncology): Perspectives, Gaps and Solutions. Annal Med Clin Oncol 3:120, 2020. DOI: 10.29011/AMCO-120.000120. https://www.gavinpublishers.com/assets/articles_pdf/1586952021article_pdf1200144087.pdf
[11] Musser ML, Berger EP, Parsons C, Kathariou S, Johannes CM. Vaccine strain Listeria monocytogenes abscess in a dog: a case report. BMC Vet Res, 15:467, 2019. DOI: 10.1186/s12917-019-2216-y https://bmcvetres.biomedcentral.com/track/pdf/10.1186/s12917-019-2216-y
[12] Musser ML, Mahaffey A, Fath M, Buettner G, Wagner B, Schneider B, Seo YJ, Mochel J, Johannes CM. In vitro cytotoxicity and pharmacokinetic evaluation of pharmacological ascorbate in dogs. Front Vet Sci, 6:385, 2019. DOI: 10.3389/fvets.2019.00385. https://www.frontiersin.org/articles/10.3389/fvets.2019.00385/full
[13] Johannes CM, Musser ML. The use of capromorelin for the clinical problem of inappetence. Today’s Veterinary Practice, pp. 70-74, July/August 2019. https://todaysveterinarypractice.com/the-use-of-capromorelin-for-the-clinical-problem-of-inappetence/
[14] Mochel JP, Ekker SC, Johannes CM, Jergens AE, Allenspach K, Bourgois-Mochel A, Knouse M, Benzekry S, Wierson W, LeBlanc AK, Kenderian SS. CAR T-cell immunotherapy in human and veterinary oncology: Changing the odds against hematologic malignancies. AAPS J, 21(3):50, 2019. DOI: 10.1208/s12248-019-0322-1. https://link.springer.com/article/10.1208/s12248-019-0322-1
[15] Garraway K, Johannes CM, Bryan A, Peauroi J, Rossi G, Zhang M, Wang C, Allenspach K, Jergens AE. Relationship of the mucosal microbiota to gastrointestinal inflammation and small cell intestinal lymphoma in cats. J Vet Intern Med, 32(5):1692-1702, 2018. DOI: 10.1111/jvim.15291. [Epub 07AUG2018] https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.15291
[16] Musser ML, Toone KE, Berger EP, Viall AK, Fox LE, Johannes CM. Selective dysmegakaryocytopoeisis secondary to chemotherapy in a dog with lymphoblastic lymphoma: a case report. J Vet Med Surg, 2(1):21, 2018. DOI: 10.4172/2574-2868.100021. https://www.imedpub.com/articles/selective-dysmegakaryocytopoiesis-secondary-to-chemotherapy-in-a-dog-with-lymphoblastic-lymphoma-a-case-report.php?aid=22992
[17] Berger EP, Johannes CM, Jergens AE, Allenspach K, Powers BE, Du Y, Mochel JP, Fox LE, Musser ML. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs. J Vet Intern Med, 32(6):2045-2053, 2018. DOI: 10.1111/jvim.15335. [Epub 11OCT2018] https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.15335
[18] Musser ML, Taikowski KL, Johannes CM, Bergman PJ. Retrospective evaluation of toceranib phosphate (PALLADIA®) use in the treatment of inoperable, metastatic or recurrent canine pheochromocytomas: 5 dogs (2014-2017). BMC Vet Res, 14(1):272, 2018. DOI: 10.1186/s12917-018-1597-7. https://bmcvetres.biomedcentral.com/track/pdf/10.1186/s12917-018-1597-7
[19] Musser M, Berger E, Flaherty HA, Fox L, Johannes CM. Marked paraneoplastic hypereosinophilia associated with a low grade, metastatic canine mast cell tumour. Vet Rec Case Rep, 6:e000563, 2018. DOI: 10.1136/vetreccr-2017-000563 [Epub 26MAY2018] https://vetrecordcasereports.bmj.com/content/vetreccr/6/2/e000563.full.pdf
[20] Filion MC, Rodrigues L, Johannes C, Masic A. The in vitro and in vivo anti-cancer potential of mycobacterium cell wall fraction (MCWF) against canine transitional cell carcinoma of the urinary bladder. Acta Veterinaria-Beograd, 67(4):477-494, 2017. DOI: 10.1515/acve-2017-0039. https://content.sciendo.com/view/journals/acve/67/4/article-p477.xml?language=en
[21] Berger EP, Johannes CM, Post GS, Rothchild G, Shiu KB, Wetzel S, Fox LE. Retrospective evaluation of toceranib phosphate (PALLADIA®) use in cats with mast cell neoplasia. J Feline Med Surg, 20(2):95-102, 2018. DOI: 10.1177/1098612X17695898. [Epub 01MAR2017] https://journals.sagepub.com/doi/pdf/10.1177/1098612X17695898
[22] Gieger TL, Nettifee-Osborne J, Hallman B, Johannes C, Clarke D, Nolan MW, Williams LE. The impact of carboplatin and toceranib phosphate on serum vascular endothelial growth factor (VEGF) and metalloproteinase-9 (MMP-9) levels and survival in canine osteosarcoma. Can J Vet Res, 81(3):199-205, 2017. PMC5508385, PMID: 28725110. https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5508385&blobtype=pdf
[23] Viall AK, McLeland SM, McQuinn ER, Ho-Eckart LK, Johannes CM. Haemophagocytic syndrome in a dog with granulomatous splenitis. Vet Rec Case Rep, 4:e000396, 2017. DOI: 10.1136/vetreccr-2016-000396. https://vetrecordcasereports.bmj.com/content/vetreccr/4/2/e000396.full.pdf
REFEREED PUBLICATIONS – IOWA STATE (SUBMITTED/IN REVIEW)
[1] Brown GK, Jones P, Campbell JE, De Ridder TR, Reddell P, Johannes CM, Pruitt JB, White J, Pittenger ST, Geller S, Kozak W, Burek-Schwarz C. Intratumoural treatment of canine high-grade mast cell tumours with tigilanol tiglate. Submitted to Vet Comp Oncol, January 2021.
[2] Coto GM, Musser ML, Tropf M, Ward JL, Seo YJ, Mochel JP, Johannes CM. A multi-institutional, retrospective analysis of prognostic factors and treatment options for presumed or confirmed canine aortic body chemodectomas. Submitted to Front Vet Sci, December 2020.
[3] Minkler S, Lucien F, Kimber M, Bourgois-Mochel A, Musser M, Johannes C, Frank I, Cheville J, Allenspach K, Mochel J. Emerging roles of urine-derived components for the management of bladder cancer: One man’s trash is another man’s treasure. Preprints, November 2020. DOI: 10.20944/preprints202011.0364.v1). Submitted to Cancers, December 2020.
[4] Sheppard-Olivares S, Bello N, Johannes CM, Hocker S, Biller B, McKee T, McMillan M, Husbands B, Wood E, Wouda RM. Management of canine insulinomas with toceranib phosphate: 30 cases (2009-2019). Submitted to BMC Vet Res, August 2020.
[5] Makielski KM, Jeffery U, Fox LE, Johannes CM, Schulte AJ, Kim JH, Husbands BD, Walz JZ, Henson MS, Modiano JF, LeVine DN. Coated platelet potential in canine cancer patients. Submitted to Am J Vet Res, January 2020.
NON-REFEREED PUBLICATIONS – IOWA STATE
[1] Johannes CM. The future is now: New oncology therapeutics impacting practice. American Veterinarian. 1.19, V.4, N.1, 2019. https://www.americanveterinarian.com/journals/amvet/2019/january2019/new-veterinary-oncology-therapeutics
[2] Johannes CM. Inappetence case reports (2). Aratana Therapeutics, educational handout for veterinarians, September 2018.
[3] Burney D, Cook A, Freeman L, Johannes C. Inappetence: Its many forms and clinical management. Expert views from a Roundtable on Canine Inappetence. Clinicians Brief/Forum, February 2018, pp. 1-5. https://www.cliniciansbrief.com/article/clinicians-forum-expert-views-roundtable-canine-inappetence
[4] Clifford C, Garrett LD, Henry C, Hohenhaus AE, Johannes C, Jones PD, Klein MK, London CA, Mitchener K, Thamm DH, Vail DM, Gloyd KS. Veterinary Oncology Roundtable: The role of prognostic factors in patient selection for canine mast cell tumor therapy with Palladia®. Zoetis (online and print distribution), 2017. https://www.zoetisus.com/products/dogs/palladia/pdf/palladia-roundtable-part-1.pdf
[5] Clifford C, Garrett LD, Henry C, Hohenhaus AE, Johannes C, Jones PD, Klein MK, London CA, Mitchener K, Thamm DH, Vail DM, Gloyd KS. Veterinary Oncology Roundtable: Palladia® treatment protocols and consensus on current best practices. Zoetis (online and print distribution), 2017. https://www.zoetisus.com/products/dogs/palladia/pdf/palladia-roundtable-part-2.pdf
BOOK CHAPTERS – IOWA STATE
Johannes CM, Musser ML. Anorexia and the Cancer Patient. Vet Clin North Am Small Anim Pract, 49(5): 837-854, 2019 DOI: 10.1016/j.cvsm.2019.04.008. [Epub 06JUN2019] https://reader.elsevier.com/reader/sd/pii/S0195561619300853?token=A7F4453D888D7DBC50BF57446214BF763C48957D79B3DFD7AF9F7EDC0E0689F492B5AE9483A066531DEBF344F18C1438
REFEREED PUBLICATIONS – PRIOR TO IOWA STATE
[1] Kidder AC, Johannes C, Obrien DP, Harkin KR, Schermerhorn T. Feline dysautonomia in the Midwestern United States: a retrospective study of nine cases. J Fel Med Surg, 10(2):130-136, 2008. DOI: 10.1016/j.jfms.2007.08.005
[2] Johannes CM, Henry CJ, Turnquist SE, Hamilton TA, Smith AN, Chun R, Tyler JW. Hemangiosarcoma in cats: 53 cases (1992-2002). J Am Vet Med Assoc, 231(12):1851-1856, 2007. DOI: 10.2460/javma.231.12.1851
[3] Cohn LA, Stoll MR, Branson KR, Roudabush AD, Kerl ME, Langdon PF, Johannes CM. Fatal hemothorax following management of an esophageal foreign body. J Am Anim Hosp Assoc, 39(3):251-6, 2003. DOI: 10.5326/0390251
[4] Cohn LA, Reeves Cook C, Priddy N, Johannes CM. What is your diagnosis? Emphysematous cystitis in a non-diabetic dog. J Am Vet Med Assoc, 218(5):703-704, 2001. PMID: 11280398
[5] Johannes CM, Cohn LA. A clinical approach to patients with fever of unknown origin. Veterinary Medicine, 95(8):633-644, 2000.